Previous studies have reported that high levels of estrogen receptor (ER) accumulation in patients with non-small cell lung cancer (NSCLC) positively feedback to activate AKT, which ultimately suppresses the expression of PTEN, leading to cisplatin resistance in NSCLC (9). Here, AKT1 is linked to non-small cell lung carcinoma.